mer        10th annynoanny ie logo_large
Post-Activity Survey and Evaluation
Specialty Pharmacy Care and Cost Management Strategies for Psoriatic Disease Therapies

April 29, 2019
QP
In an effort to better determine the overall effectiveness of continuing education activities, we are conducting a brief survey. Listed below are questions for which we would like your responses. All information obtained will be used and reported in aggregate only, without individual attribution. Thank you for your participation.

If you have any questions please contact us at info@impactedu.net.

*All questions are required.
Q1.1 Now that you have participated in this activity, how confident are you in your ability to assess current evidence-based treatment recommendations for patients with psoriatic disease?
 
Q1.2 The National Psoriasis Foundation’s consensus target reduction in body surface area (BSA) three months after initiating treatment is ___?
 
Q1.3 Which of the following chronic comorbid conditions are individuals with psoriasis at highest risk of developing?
 
Q1.4 Now that you have participated in this activity, how confident are you in your ability to employ and/or recommend clinical care pathways that can be used to enhance psoriatic disease management?
 
Q1.5 Within your plan or practice setting when applicable, how often do you plan to employ specialty pharmacy services that include interventions that will impact patient adherence to biologic therapies for psoriatic disease?   (1 = Never, 6 = Always)
(Please select the appropriate number on the scale below or mark if this decision or authority is outside your usual scope of practice)  
 
Evaluation Form

Medical Education Resources, Inc. is committed to excellence in continuing education, and your opinions are critical to us in this effort.  To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form.

You must complete this evaluation form to receive acknowledgment for completing this activity.
Q1.6 What is your specialty?
 
  Q1.6a. Please explain "other".
Q1.7 What best describes your primary role?
 
 
 
 
 
 
 
 
 
 
 
   
  Q1.7a. Please explain "other".
Q1.8 How many years have you been in your area of responsibility?
 
Q1.9 Approximately how many patients with psoriatic disease are being managed in your organization, practice setting, or affiliated organizations?
 
Q1.10 Rate how well the activity supported your achievement of these learning objectives.
           
  Explain the pathophysiology and immunologic pathways of psoriatic disease          
  Align psoriatic disease specialty drug treatment algorithms with evidence-based treatment recommendations          
  Utilize care pathways as cost management and appropriate use tools in psoriatic disease          
  Employ specialty pharmacy and disease management services for psoriatic disease patients          
Q1.11 Please select the extent to which you agree/disagree that the speakers achieved the following:
Effective in Presenting the Material
           
  Alan Menter, MD          
  Robin Dore, MD          
  Michael Zeglinski, RPh          
Q1.12 Please select the extent to which you agree/disagree that the speakers achieved the following:
Avoided Commercial Bias or Influence
           
  Alan Menter, MD          
  Robin Dore, MD          
  Michael Zeglinski, RPh          
Q1.13 Rate how well the activity achieved the following.
           
  The content was evidence based          
  The educational material provided useful information for my practice          
  The activity enhanced my current knowledge base          
  The activity provided appropriate and effective opportunities for active learning (eg, case studies, discussion, Q&A, etc)          
  The opportunities provided to assess my own learning were appropriate (eg, questions before, during or after the activity)          
Q1.14 Based upon your participation in this activity, do you intend to change your practice and/or administrative behavior?
 
 
Q1.15
Q1.16 If you plan to change your practice and/or administrative behavior, what type of changes do you plan to implement?
(check all that apply)
 
 
  Q1.16o. Please specify "other".
Q1.17 How confident are you that you will be able to make your intended changes?
 
 
Q1.18 Which of the following do you anticipate will be the primary barrier to implementing these changes?
 
 
  Q1.18o. Please specify "other".
Q1.19 Was the content of this activity fair, balanced, objective, and free of commercial bias?
 
 
  Q1.19o. Please explain.
Q1.20
Q1.21
Q1.22
Q1.23
Q1.24
Q1.25
Q1.26
Q1.27
Q1.28
Q1.29 Type of Credit
 
Q1.30
Q1.31 TO CLAIM CREDIT: Upon submission of your evaluation you will be redirected to a web page with instructions. You must follow the instructions to claim credit. Submission of the evaluation alone will not provide credit.
 
 


If you have any questions please email info@impactedu.net.